The Foundation for the National Institutes of Health (FNIH) will award more than $3 and a half million to further the study of Type 2 Diabetes (T2D) as part of an unprecedented collaboration to develop new ways to diagnose and treat several pressing diseases.
The Foundation for the National Institutes of Health (FNIH) has selected Karl Deisseroth, M.D., Ph.D., as the 2015 winner of the Lurie Prize in Biomedical Sciences for the development of optogenetics and CLARITY as tools to study the functions of cells, especially neurons. Dr. Deisseroth is being recognized for leading the development of optogenetics, a technology for controlling cells with light to determine function, as well as for CLARITY, a method for transforming intact organs into transparent polymer gels to allow visualization of biological structures with high resolution and detail. The Lurie Prize will be presented to Dr. Deisseroth on May 20, 2015 in Washington, D.C.
On Wednesday, May 20, the Foundation for the National Institutes of Health (FNIH) will bring together leaders from biomedical science, the biotech and pharmaceutical industries, philanthropy and business, for the 2015 FNIH Award Ceremony and presentation of the Lurie Prize in Biomedical Sciences.
In the first donation of its kind for the Foundation for the National Institutes of Health (FNIH), the John & Marcia Goldman Foundation has awarded $25,000 to support Ebola research in West Africa conducted by the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health.
The Lung-MAP trial, a multi-drug, multi-sub-study, biomarker-driven clinical trial for patients with advanced squamous cell lung cancer, that launched on June 16th 2014, today announced that it has expanded to an additional 169 locations throughout the United States. They join 85 locations that have been participating in the trial since the June launch. All locations can be found here: http://www.lung-map.org/locations
A unique public-private collaboration among the National Cancer Institute (NCI), part of the National Institutes of Health, SWOG Cancer Research, Friends of Cancer Research (Friends), the Foundation for the National Institutes of Health (FNIH), five pharmaceutical companies (Amgen, Genentech, Pfizer, AstraZeneca, and AstraZeneca’s global biologics R&D arm, MedImmune), and Foundation Medicine today announced the initiation of the Lung Cancer Master Protocol (Lung-MAP) trial.
Low muscle mass and weakness are important contributors to sarcopenia, a common and potentially disabling condition in older adults. Diagnostic criteria have been proposed, but no consensus yet exists.
The Foundation for the National Institutes of Health (FNIH) has selected Jennifer Doudna, Ph.D., a Professor from the University of California, Berkeley, as the second winner of its Lurie Prize in the Biomedical Sciences. Doudna, a Howard Hughes Investigator and Professor of Biochemistry, Biophysics and Structural Biology, will be presented the Lurie Prize medal and a $100,000 honorarium on May 20 in Washington, D.C.
The I-SPY 2 TRIAL, a randomized phase II clinical trial for breast cancer launched through a unique partnership with the Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium and sponsored by QuantumLeap Healthcare Collaborative has graduated the first two drugs from its innovative, multidrug standing platform trial.
The National Institutes of Health has selected eight projects to receive support to answer some of the most fundamental problems on traumatic brain injury, including understanding long-term effects of repeated head injuries and improving diagnosis of concussions.